Exelixis, Inc. Initiates Randomized Phase 2 Clinical Trial Of Cabozantinib Plus Abiraterone In Chemotherapy-Naïve Patients With Metastatic Castration-Resistant Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced that it has initiated a phase 2 clinical trial comparing cabozantinib plus abiraterone and prednisone (abiraterone/prednisone) versus abiraterone/prednisone in patients with castration-resistant prostate cancer (CRPC) who have bone metastases and have not been previously treated with chemotherapy. The primary endpoint for the randomized, open-label trial is radiographic progression-free survival (PFS).

Help employers find you! Check out all the jobs and post your resume.